JP2005503383A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005503383A5 JP2005503383A5 JP2003520752A JP2003520752A JP2005503383A5 JP 2005503383 A5 JP2005503383 A5 JP 2005503383A5 JP 2003520752 A JP2003520752 A JP 2003520752A JP 2003520752 A JP2003520752 A JP 2003520752A JP 2005503383 A5 JP2005503383 A5 JP 2005503383A5
- Authority
- JP
- Japan
- Prior art keywords
- adrenal
- pharmaceutical composition
- hydrocortisone
- disease
- caused
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001919 adrenal Effects 0.000 claims 12
- JYGXADMDTFJGBT-VWUMJDOOSA-N Cortisol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 10
- 229960000890 hydrocortisone Drugs 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 230000004064 dysfunction Effects 0.000 claims 8
- 206010010356 Congenital anomaly Diseases 0.000 claims 6
- 201000004304 Addison's disease Diseases 0.000 claims 4
- 206010020880 Hypertrophy Diseases 0.000 claims 4
- 206010001347 Adrenal disease Diseases 0.000 claims 2
- 206010001367 Adrenal insufficiency Diseases 0.000 claims 2
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 claims 2
- 206010036049 Polycystic ovary Diseases 0.000 claims 2
- 229960003290 cortisone acetate Drugs 0.000 claims 2
- 230000003111 delayed Effects 0.000 claims 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 2
- 230000002459 sustained Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Claims (12)
- ヒドロコルチゾンもしくはこれの機能的変異体および送達ビヒクルを含む、副腎機能不全の処置用医薬組成物であって、ここで該送達ビヒクルが、該ヒドロコルチゾンもしくはこれの機能的変異体の、遅らせかつ持続された放出をもたらすものである医薬組成物。
- 前記機能的変異体が：ヒドロコルチゾール；コルチゾール；またはコルチゾンアセテートである、請求項１に記載の医薬組成物。
- 前記医薬組成物がヒドロコルチゾンを含む、請求項１に記載の医薬組成物。
- 前記副腎機能不全が：１次または２次的な副腎疾患、先天性副腎肥大、後発した先天性副腎肥大、多嚢胞卵巣疾患、およびアジソン病からなる群から選択される病状により引き起こされる、請求項１〜３のいずれか１項に記載の医薬組成物。
- 前記副腎機能不全が先天性副腎機能不全により引き起こされる、請求項４に記載の医薬組成物。
- 前記副腎機能不全がアジソン病により引き起こされる、請求項４に記載の医薬組成物。
- 副腎機能不全の治療における利用のための医薬品の製造に関しての、ヒドロコルチゾンもしくはこれの機能的変異体および送達ビヒクルを含む医薬組成物の使用であって、ここで該送達ビヒクルが、該ヒドロコルチゾンもしくはこれの機能的変異体の遅らせかつ持続された放出をもたらすものである使用。
- 前記機能的変異体が：ヒドロコルチゾール；コルチゾール；またはコルチゾンアセテートである、請求項７に記載の使用。
- 前記医薬組成物がヒドロコルチゾンを含む、請求項７に記載の使用。
- 前記副腎機能不全が：１次または２次的な副腎疾患、先天性副腎肥大、後発した先天性副腎肥大、多嚢胞卵巣疾患、およびアジソン病からなる群から選択される病状により引き起こされる、請求項７〜９のいずれか１項に記載の使用。
- 前記副腎機能不全が先天性副腎機能不全により引き起こされる、請求項１０に記載の使用。
- 前記副腎機能不全がアジソン病により引き起こされる、請求項１０に記載の使用。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0119848.0A GB0119848D0 (en) | 2001-08-15 | 2001-08-15 | Delayed and sustained drug release |
| PCT/GB2002/003631 WO2003015793A1 (en) | 2001-08-15 | 2002-08-08 | Delayed and sustained drug release |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005503383A JP2005503383A (ja) | 2005-02-03 |
| JP2005503383A5 true JP2005503383A5 (ja) | 2006-01-05 |
Family
ID=9920405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003520752A Pending JP2005503383A (ja) | 2001-08-15 | 2002-08-08 | 遅らせかつ持続された薬剤放出 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20050037074A1 (ja) |
| EP (1) | EP1416938A1 (ja) |
| JP (1) | JP2005503383A (ja) |
| CA (1) | CA2493349A1 (ja) |
| GB (1) | GB0119848D0 (ja) |
| WO (1) | WO2003015793A1 (ja) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1448205B1 (en) * | 2001-10-05 | 2011-03-23 | Zalicus Inc. | Combinations for the treatment of immunoinflammatory disorders |
| TW200517114A (en) * | 2003-10-15 | 2005-06-01 | Combinatorx Inc | Methods and reagents for the treatment of immunoinflammatory disorders |
| GB0400031D0 (en) * | 2004-01-03 | 2004-02-04 | Univ Sheffield | Depression treatment |
| SE0401031D0 (sv) | 2004-04-22 | 2004-04-22 | Duocort Ab | A new glucocorticoid replacement therapy |
| US20080003213A1 (en) * | 2006-05-22 | 2008-01-03 | Jan Lessem | Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein, interleukin-6, or interferon-gamma levels |
| GB0623740D0 (en) * | 2006-11-28 | 2007-01-10 | Diurnal Ltd | Treatment of disease |
| US20090075955A1 (en) * | 2007-09-19 | 2009-03-19 | Combinatorx, Inc. | Therapeutic regimens for the treatment of immunoinflammatory disorders |
| AU2008338980A1 (en) * | 2007-12-17 | 2009-06-25 | Zalicus Inc. | Therapeutic regimens for the treatment of immunoinflammatory disorders |
| GB0817120D0 (en) * | 2008-09-19 | 2008-10-29 | Diurnal Ltd | Treatment of adrenal insufficiency |
| NZ595428A (en) * | 2009-04-07 | 2013-04-26 | Duocourt Pharma Ab | Improved glucocorticoid therapy |
| MX337429B (es) | 2010-05-20 | 2016-03-04 | Duocort Pharma Ab | Posologia y administracion de composiciones basadas en glucocortticoides. |
| GB201202433D0 (en) | 2012-02-13 | 2012-03-28 | Diurnal Ltd | Controlled drug release |
| ES2906778T3 (es) | 2015-03-30 | 2022-04-20 | Corcept Therapeutics Inc | Uso de antagonistas del receptor de glucocorticoides en combinación con glucocorticoides para tratar la insuficiencia suprarrenal |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5792476A (en) * | 1996-12-19 | 1998-08-11 | Abigo Medical Ab | Sustained release glucocorticoid pharmaceutical composition |
| US5788987A (en) * | 1997-01-29 | 1998-08-04 | Poli Industria Chimica Spa | Methods for treating early morning pathologies |
| DE19718012C1 (de) * | 1997-04-29 | 1998-10-08 | Jenapharm Gmbh | Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe |
| DE10012555A1 (de) * | 2000-03-15 | 2001-09-20 | Merck Patent Gmbh | Glucocorticoide in einer Modified Release-Formulierung |
-
2001
- 2001-08-15 GB GBGB0119848.0A patent/GB0119848D0/en not_active Ceased
-
2002
- 2002-08-08 WO PCT/GB2002/003631 patent/WO2003015793A1/en active IP Right Grant
- 2002-08-08 US US10/486,700 patent/US20050037074A1/en not_active Abandoned
- 2002-08-08 CA CA002493349A patent/CA2493349A1/en not_active Abandoned
- 2002-08-08 EP EP02751394A patent/EP1416938A1/en not_active Withdrawn
- 2002-08-08 JP JP2003520752A patent/JP2005503383A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005503383A5 (ja) | ||
| JP2007502287A5 (ja) | ||
| WO2006135638A3 (en) | Tanaproget compositions containing ethinyl estradiol | |
| TW200635617A (en) | Multiparticulate pharmaceutical form comprising mucoadhesively formulated nucleic acid active ingredients, and a process for producing the pharmaceutical form | |
| JP2006520797A5 (ja) | ||
| JP2008535850A5 (ja) | ||
| EP1571153A3 (en) | A process for the preparation of drospirenone | |
| WO2008057420A3 (en) | Extended triterpene derivatives | |
| JP2004518656A5 (ja) | ||
| WO2007048219A3 (en) | Sustained drug release composition | |
| JP2008521488A5 (ja) | ||
| JP2005533005A5 (ja) | ||
| JP2003503454A5 (ja) | ||
| ATE493132T1 (de) | Arzneimittel umfassend wenigstens ein gestagen | |
| JP2009521419A5 (ja) | ||
| JP2008534533A5 (ja) | ||
| WO2005077968A8 (en) | 17-methylene-or 17 - spiro - cyclopropane 7 - substituted estra - 1, 3, 5 (10) - triene derivatives with anti - estrogenic activity | |
| AU2002224926A1 (en) | Novel medicament compositions based on anticholinesterase drugs and on a steroid | |
| JP2008515980A5 (ja) | ||
| JP2010539153A5 (ja) | ||
| WO2005011614A8 (en) | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease | |
| WO2007062483A8 (en) | Increasing pregnancy rates | |
| WO2006054162A8 (en) | Azabicyclic muscarinic receptor antagonists | |
| SE0200895D0 (sv) | New pharmaceutical composition | |
| IL266823A (en) | Use of chymase inhibitors to treat endometriosis, post-operative fibrosis and diseases associated with fibrosis formation |